KIT and gastrointestinal stromal tumor: Sunitinib became standard second-line therapy after improving outcomes in patients progressing on imatinib [33,34,35], with differential efficacy across molecular subsets—including enhanced activity in tumors with KIT exon 9 mutations and specific secondary mutations [36,37]—highlighting the heterogeneity of GIST evolution and reinforcing the need for molecular profiling.